Regenerex Pharma (RGPX) 10-Q 13 Nov 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2018	Nov. 12, 2018
Document And Entity Information
Entity Registrant Name	PEPTIDE TECHNOLOGIES, INC.
Entity Central Index Key	1,357,878
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		127,112,660
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018
Entity Small Business	true
Is Entity Emerging Growth Company?	false

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 1,083	$ 1,728
Total Current Assets	1,083	1,728
Website	10,667	13,341
Total Assets	11,750	15,069
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	53,454	37,870
Related-party advances	67,592	67,113
Accrued compensation	221,192	221,192
Other accrued liabilities	14,000	10,000
Total Current Liabilities	356,238	336,175
Stockholders' Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of September 30, 2018 and March 31, 2018	127,113	127,113
Additional paid-in capital	731,963	731,963
Accumulated deficit	(1,203,564)	(1,180,182)
Total Stockholders' Deficit	(344,488)	(321,106)
Total Liabilities and Stockholders' Deficit	$ 11,750	$ 15,069

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	127,112,660	127,112,660
Common stock, shares outstanding	127,112,660	127,112,660

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses
General and administrative	$ 4,820	$ 8,144	$ 23,389	$ 25,247
Total Operating Expenses	4,820	8,144	23,389	25,247
Operating Loss	(4,820)	(8,144)	(23,389)	(25,247)
Other Expense
Foreign currency loss	11	17	7	17
Net Loss	$ (4,809)	$ (8,127)	$ (23,382)	$ (25,230)
Basic and Diluted Loss per Common Share
Weighted Average Number of Common Shares Outstanding	127,112,660	156,062,660	127,112,660	156,062,660

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows From Operating Activities:
Net loss	$ (23,382)	$ (25,230)
Adjustments to reconcile net loss to cash flows used in operating activities
Depreciation and amortization	2,674
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	19,584	5,000
Net cash used for operating activities	(1,124)	(20,230)
Cash Flows From Investing Activities:
Website development		(16,000)
Net cash used for investing activities		(16,000)
Cash Flows From Financing Activities:
Related-party advances	479	39,536
Net cash provided by financing activities	479	39,536
(Decrease) increase in cash and equivalents	(645)	3,306
Cash and cash equivalents, beginning of period	1,728
Cash and cash equivalents, end of period	$ 1,083	$ 3,306

Nature Of Operations

Nature Of Operations	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operations	NOTE 1 – NATURE OF OPERATIONS Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties. The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly. The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies. The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

Going Concern

Going Concern	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,203,564 as of September 30, 2018. The Company also has excess liabilities over assets of $344,488. These factors raise doubt about the Company’s ability to continue as a going concern. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017. Recent Accounting Pronouncements The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 – RELATED PARTY TRANSACTIONS The Company’s Chief Financial Officer (“CFO”) advanced $479 and $39,536 to the Company during the six months ended September 30, 2018 and 2017, respectively, to pay for operating expenses and website development costs. The advances are due on demand and carry no interest. The related party advances totaled $67,592 and $67,113 as of September 30, 2018 and March 31, 2018, respectively.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	NOTE 6 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 7 – SUBSEQUENT EVENTS In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

Nature Of Operations (Details N

Nature Of Operations (Details Narrative)	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Nov. 18, 2005

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 1,203,564	$ 1,180,182
Total Stockholders' Deficit	$ 344,488	$ 321,106

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Website Estimated Useful Life			3 years
Amortization Expense, Website	$ 1,344		$ 2,674

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017
Related party advances	$ 67,592	$ 67,113
Chief Financial Officer [Member]
Related party advances	$ 479		$ 39,536

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Oct. 31, 2018
Subsequent Events [Abstract]
Description	In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing.